Medication info

Dapduo Sustained Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Hanmi Pharm Co., Ltd.
Appearance
Yellow, biconvex, oval-shaped sustained-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP*5)], 200 tablets/bottle, 30 tablets/bottle
Approval status
Active

MFDS item code 202300151 · Approved 2023.01.06

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Ingredients

Manufacturer
Hanmi Pharm Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular diseases
  • cardiovascular risk factors
View approved original text

This medication helps control blood sugar levels in adult patients with type 2 diabetes by using dapagliflozin and metformin together. It assists in effectively managing blood sugar in conjunction with dietary and exercise therapy. In particular, caution must be exercised based on expert guidelines regarding the cardiovascular effects of dapagliflozin in patients who have insufficient blood sugar control and have cardiovascular disease or risk factors.

How to take

Adult dose

The dose of this medication should be individualized based on the patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as two 5mg/1000mg tablets. Patients with no prior history of antidiabetic drug therapy for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients with no prior history of antidiabetic drug therapy, the recommended starting dose of this medication is one 5mg/500mg or 10mg/500mg tablet once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions to metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medication should provide the patient’s current metformin dose or an appropriate dose therapeutically close to it. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. For patients switching from concomitant dapagliflozin and metformin therapy to this medication, the dose may be started at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be monitored closely and the dose adjusted appropriately. When this medication is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Since changes may cause changes in glycemic control, any change in treatment for patients with type 2 diabetes should be made under close monitoring. This medication must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is required in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and without other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication should be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted through the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient section).

Precautions

This medication is used for diabetes treatment and helps manage blood sugar levels. When taking this medicine, one should be cautious of rare side effects such as severe lactic acidosis. Lactic acidosis is a potentially dangerous condition where lactic acid accumulates excessively in the body. Additionally, careful monitoring is required when used in conjunction with insulin or sulfonylurea medications, as it may cause severe hypoglycemia. Patients with poor kidney function, dehydration, severe infections, or heart issues should not take this medication. Before and after surgeries or tests using radioactive iodine contrast agents, the use of this medication should be temporarily discontinued, and it should only be resumed after confirming normal renal function. Pregnant or breastfeeding women should not use this medication, and patients with specific genetic disorders such as lactose intolerance should also avoid it. Elderly patients or those with diminished kidney function should undergo kidney function tests before taking this medication, and regular monitoring of kidney function should continue during treatment. This medication can cause a decrease in fluid volume or low blood pressure, so patients with low blood pressure or those taking diuretics should be especially cautious. Genital infections and urinary tract infections may occur frequently, so patients should consult a healthcare professional immediately if infection symptoms appear. Vitamin B12 levels may decrease, so it's advisable to check vitamin B12 levels during long-term use. Excessive alcohol consumption can increase the risk of side effects associated with this medication, so it should be avoided. This medication may cause hypoglycemia, and dosage adjustments may be necessary when taken with insulin or other hypoglycemic agents. In case of overdose, seek immediate medical attention for appropriate treatment. During treatment, dizziness may occur while driving or operating machinery, so caution is advised. Lastly, this medication should be stored out of reach of children and kept in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • reduced fluid volume
  • thirst
Show 83 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • external genital itching
  • genital itching
  • increased hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • increased serum creatinine
  • increased blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fractures
  • gastrointestinal stromal tumors
  • lung malignant neoplasms
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcers
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • paresthesia
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenovirus conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • neurogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture. Moreover, it is best stored at room temperature, which is neither too hot nor too cold, between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

Yellow, biconvex, oval-shaped sustained-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP*5)], 200 tablets/bottle, 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.